Johnson & Johnson (J&J) is aiming to further augment its portfolio of autoimmune disease treatments as the pharma giant has agreed to acquire Momenta Pharmaceuticals Inc in an all cash deal worth $6.5 billion, J&J said on Wednesday. Momenta's experimental therapy, nipocalimab,...